Drug intelligence / Profile preview

AK3280 Cream

Development stage: Unknown
Lead developer: Ark Biosciences
Modality: Small Molecules
Administration: Topical

Overview

AK3280 Cream (also known as AK3287) is an innovative topical cream formulation designed specifically for the treatment of hypertrophic scars. It is derived from AK3280, which is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. The cream formulation works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix, thereby exerting its therapeutic effect on fibrotic conditions of the skin.

Targets

LPAR1 (Lysophosphatidic acid receptor 1)

Beyond the preview

Go deeper on AK3280 Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK3280 Cream.

Explore the full profile